Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$226.3M
72M shares
52-week range
$2.83 – $9.45
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
4.0
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
www.siga.comNo one on the platform currently holds SIGA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 475,013 | $2.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-07 | $0.6000 | 2026-04-23 |
| 2025-04-29 | $0.6000 | 2025-05-15 |
| 2024-03-25 | $0.6000 | 2024-04-11 |
No one on the platform has traded SIGA yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 40.9% | 81.9% | — | — | — | |
| Rev. Growth % | -31.8% | -5.4% | ||||
| Profit Margin % | 24.6% | 39.7% | -25.5% | |||
| Free Cash Flow Margin % | 45.6% | 38.9% | -64.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +16.5% on the P/E track.
At today's price, your expected annual return is +19.9% on the P/E track.
At today's price, your expected annual return is +22.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $60M | -38.6% | $1.70 | $1.70–$1.70 | 1.8× | 1 |
| 2027 | $162M | +170.7% | $1.08 | $1.08–$1.08 | 2.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| SIGASIGA Technologies, Inc. | $2.98 | -5.40% | $214M | — |
| AQSTAquestive Therapeutics, Inc. | $4.81 | -1.43% | $603M | — |
| CTMXCytomX Therapeutics, Inc. | $2.69 | -15.94% | $586M | — |
| DRIODarioHealth Corp. | $6.75 | -4.80% | $49M | — |
| EBSEmergent BioSolutions Inc. | $6.36 | -0.31% | $328M | — |
| ESPREsperion Therapeutics, Inc. | $3.18 | +0.00% | $661M | — |
Source: Financial Modeling Prep · peers by sector/industry
| OLMAOlema Pharmaceuticals, Inc. | $9.78 | -4.96% | $854M | — |
$SIGA https://www.science.org/content/article/chilling-warning-or-overreaction-ai-bioweapons-report-divides-experts
View on StockTwits ↗$SIGA Another researcher used Claude to write a funding application to genetically alter orthopoxviruses, the family that includes smallpox and mpox, so they could better dodge immune defenses. https://www.celinegounder.com/p/anthropic-claude-ai-bioweapons-biosecurity
View on StockTwits ↗
$SIGA https://www.science.org/content/article/outrage-greets-nih-pact-could-funnel-biodefense-research-funds-pentagon
View on StockTwits ↗$SIGA https://media.defense.gov/2026/Sep/04/2003992359/-1/-1/0/INTERAGENCY-AGREEMENT-NIH-AND-DOW-REDACTED.PDF
View on StockTwits ↗$SIGA Department of war made new agrements $SIGA $EBS
View on StockTwits ↗
$SIGA big volume and up 10-cents. Seems like a no-brainer buying opportunity. Apparently, nobody follows this stock.
View on StockTwits ↗$SIGA How many shares of SIGA have our congress/senate people bought "lately"?
View on StockTwits ↗$SIGA all that volume and no price movement. Strange times.
View on StockTwits ↗
$SIGA https://archive.ph/onT6F In an hourlong interview, he said his industry was downplaying the risks, which he believes include mass unemployment and bioterrorism.
View on StockTwits ↗$SIGA https://www.tipranks.com/news/company-announcements/siga-technologies-earnings-call-highlights-q2-rebound
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.